Table 3.
Influence of TCM Combined Targeted therapy.
| Cancers | Type | Formulation | Herbal medicine | Targeted therapy | Effect of Combination | Upregulate | Downregulate | Refs. |
|---|---|---|---|---|---|---|---|---|
| NSCLC | Clinical | Compound (Classic, oral) | Xuefu Zhuyu Decoction (Angelica, peach kernel, chuanxiong, safflower, red peony root, achyranthes, bupleurum, citrus aurantium, platycodon, habitat, mountain mushroom, oldenlandia diffusa, shuyangquan, gecko, licorice) |
TCM + gefitinib/erlotinib vs gefitinib/erlotinib = 39 vs 39 | DCR 56.4% vs 48.7% (p<0.05) | T cell, Th, Tc | Protease activated receptor (PAR)-1 expression in tumor tissue | Liet al. (82) |
| Hepatocellular Carcinoma | Clinical | Compound (Listed drug, injection) | Shenqi Fuzheng Injection (Codonopsis, Astragalus) |
TCM + sorafenib vs sorafenib = 44 vs 44 | DCR 97.7% vs 86.4% (p<0.05) | CD4+ | CD8+, CXCR3, miR-103 | Lu et al. (83) |
| Ovarian cancer |
Clinical | Compound (Self-made, oral) | Yiqi Yangyin Decoction (Seres yam, Astragalus, Habitat, Polygonatum, Scrophulariaceae, Ligustrum lucidum, Zingiber turmeric, Shanzi fungus Prunella vulgaris, Platycodon grandiflorum, Jujube) |
TCM + bevacizumab vs bevacizumab = 43 vs 37 | / | CD3+, CD4+, CD4+/CD8+, NK IL-2, INF-γ |
CD4+CD25+, IL-6, IL-10, VEGF, CD133, DDX4 | Guli et al. (84) |
| HCC cells | in vitro and in vivo | Compound (Listed drug, injection) | Compound Kushen Injection (Sophora flavescens, Berberis vulgaris uniseriale) |
sorafenib | Enhanced the anticancer activity of sorafenib at a subclinical dose with no obvious side effects. | triggering TNFR1, mediated NF-κB and p38 MAPK signaling cascades | / | Yang et al. (85) |
| Gastric AGS cells | in vitro | Monomer component | Astragalus polysaccharide (APS) | apatinib | Remarkable increase in apoptosis | / | p-AKT, MMP-9 | Wu et al. (86) |
| Pancreatic cancer cell lines | in vitro | Monomer component | Astragalus polysaccharide (APS) | apatinib | Enhanced inhibitory effects on cell migration and invasion, and increased cell apoptosis percentage | / | p-AKT, p-ERK, MMP-9 | Wu et al. (87) |
| HepG2 xenografts | in vivo | Compound (Classic, oral) | PHY906 (KD018) | sorafenib | potentiate the anti-hepatoma activity | hMCP1, M1/M2, AMPKα-P and ULK1-S555-P, ERK1/2-P | / | Lam et al. (88) |